Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: A work in progress

Current Cancer Drug Targets

Volumn 2, Issue 4, 2002, Pages 337-353

  Gabrielli, B G ^a   Johnstone, R W ^a   Saunders, N A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; ARGININE BUTYRATE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BENZAMIDE DERIVATIVE; BUTYRIC ACID DERIVATIVE; CHAP 31; CYCLOPEPTIDE; DEPSIPEPTIDE; DEXAMETHASONE; FLUOROURACIL; FR 901228; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INDOMETACIN; INTERLEUKIN 2; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; RETINOIC ACID; TETRAPEPTIDE; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; NONHUMAN; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 0036889263     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023333818     Document Type: Review

References (119)

1. Johnson, C. A.; White, D. A.; Lavender, J. S.; O'Neill, L. P.; and Turner, B. M. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J. Biol. Chem. 2002, 277, 9590-9597.
2. Kim, G. D.; Choi, Y. H.; Dimtchev, A.; Jeong, S. J.; Dritschilo, A.; Jung, M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem. 1999, 274, 31127-31130.
3. Lee, H. J.; Chun, M.; Kandror, K. V. Tip60 and HDAC7 interact with the endothelin receptor a and may be involved in downstream signaling. J. Biol. Chem. 2001, 276, 16597-16600.
4. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
5. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes & Develop. 1998, 12, 599-606.
6. Cameron, E. E.; Bachman, K. E.; Myohanen, S.; Herman, J. G.; Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics 1999, 21, 103-107.
7. Saunders, N. A.; Popa, C.; Serewko, M. M.; Jones, S. J.; Dicker, A. J.; Dahler, A. L. Histone deacetylase inhibitors: Novel anticancer agents. Exp. Opin. Invest. Drugs 1999, 8, 1611-1621.
8. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 2000, 403, 41-45.
9. Jenuwein, T.; Allis, C. D. Translating the histone code. Nature 2001, 293, 1074-1093.
10. Kouzarides, T. Acetylation: A regulatory modification to rival phosphorylation?. EMBO J. 2000, 19, 1176-1179.
11. Taunton, J.; Hassig, C. A.; Schreiber, S. L. A Mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
12. Yang, W. M., Yao, Y. L.; Sun, J. M.; Davie, J. R.; Seto, E. Isolation and characterisation of cDNA's corresponding to an additional member of the human histone deacetylase gene family. J Biol. Chem. 1997, 272, 28001-28007.
13. Emiliani, S.; Wolfgang, F.; Van Lint, C.; Al-Abed, Y.; Verdin, E. Characeterisation of a human RPD3, HDAC3. Proc. Natl. Acad. Sci. USA 1998, 95, 2795-2800.
14. Hu, E.; Chen, Z.; Fredrickson, T.; Zhu, Y.; Kirkpatrick, R.; Zhang, G. F.; Johanson, K.; Sung, C. M.; Liu, R.; Winkler, J. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J. Biol. Chem. 2000, 275, 15254-15264.
15. Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hdalp. Proc. Natl. Acad. Sci. USA 1999, 96, 4868-4873.
16. Zhou, X.; Marks, P. A.; Rifkind, R. A.; Richon, V. M. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA 2001, 98, 10572-10577.
17. Guardiola, A. R.; Yao, T. P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 2002, 277, 3350-3356.
18. Shore, D. The Sir2 protein family: A novel deacetylase for gene silencing and more. Proc. Natl. Acad. Sci. USA 2000, 97, 14030-14032.
19. Bannister, A. J.; Zegerman, P.; Partridge, J. F.; Miska, E. A.; Thomas, J. O.; Allshire, R. C.; Kouzarides, T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001, 410, 120-124.
20. Polioudaki, H.; Kourmouli, N.; Drosou, V.; Bakou, A.; Theodoropoulos, P. A.; Singh, P. B.; Giannakouros, T.; Georgatos, S. D. Histones H3/H4 form a tight complex with the inner nuclear membrane protein LBR and heterochromatin protein 1. EMBO Reports 2001, 2, 920-925.
21. Lachner, M.; O'Carroll, D.; Rea, S.; Mechtler, K.; Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001, 410, 116-120.
22. Czermin, B.; Schotta, G.; Hulsmann, B. B.; Brehm, A.; Becker, P. B.; Reuter, G.; Imhof, A. Physical and functional association of SU(VAR)3-9 and HDAC1 in drosophila. EMBO Reports 2001, 2, 915-919.
23. Vandel, L.; Nicolas, E.; Vaute, O.; Ferreira, R.; Ait-Si-Ali, S.; Trouche, D. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol. Cell. Biol. 2001, 21, 6484-6494.
24. Cervoni, N.; Szyf, M. Demethylase activity is directed by histone acetylation. J. Biol. Chem. 2001, 276, 40778-40787.
25. Ragione, F. D.; Criniti, V.; Pietra, V. D.; Borriello, A.; Oliva, A.; Indaco, S.; Yamamoto, T.; Zappia, V. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Letters 2001, 499, 199-204.
26. Bernstein, B. E.; Tong, J. K.; Schreiber, S. L. Genomewide studies of histone deacetylase function in yeast. Proc. Natl. Acad. Sci. USA 2000, 97, 13708-13713.
27. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
28. Yoshida, M.; Furumai, R.; Nishiyama, M.; Komatsu, Y.; Nishino, N.; Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001, 48, S20-S26.
29. Seigneurin Berny, D.; Verdel, A.; Curtet, S.; Lemercier, C.; Garin, J.; Rousseaux, S.; Khochbin, S. Identification of Components of the murine histone deacetylase 6 complex: Link between acetylation and ubiquitination signaling pathways. Mol. Cell. Biol. 2001, 21, 8035-8044.
30. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S. W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Med. 2001, 7, 437-443.
31. Pili, R.; Kruszewski, M. P.; Hager, B. W.; Lantz, J.; Carducci, M. A. Combination of phenylabutyrate and 13-Cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Research 2001, 61, 1477-1485.
32. Brinkmann, H.; Dahler, A. L.; Popa, C.; Serewko, M. M.; Parsons, P. G.; Gabrielli, B. G.; Burgess, A. J.; Saunders, N. A. Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J. Biol. Chem., 2001, 276, 22491-22499.
33. Deroanne, C. F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J. M.; Nusgens, B. V.; Castronovo, V. Histone deacetylase inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signalling. Oncogene 2002, 21, 427-436.
34. Richon, V. M.; Emiliani, S.; Verdini, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 1998, 95, 3003-3007.
35. Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin a and Trapoxin: Novel Chemical Probes for the Role of Histone Acetylation in Chromatin Structure and Function. BioEssays 1995, 17, 423-430.
36. He, L. Z.; Guidez, F.; Tribioli, C.; Peruzzi, D.; Ruthardt, M.; Zelent, A.; Pandolfi, P. P. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nature Genetics 1998, 18, 126-135.
37. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassoni, L.; Gelmetti, V.; Cioce, M.; Fanelli, M.; Ruthardt, M.; Ferrara, F. F.; Zamir, I.; Seiser, C.; Grignani, F.; Lazar, M. A.; Minucci, S.; Pelicci, P. G. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391, 815-818.
38. Lin, R. J.; Nagy, L.; Inoue, S.; Shao, W.; Miller, W. H.; Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391, 811-814.
39. Lu, J.; McKinsey, T. A.; Zhang, C. L.; Olson, E. N. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell 2000, 6, 33-244.
40. McKinsey, T. A.; Zhang, C. L.; Lu, J.; Olson, E. N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000, 408, 106-111.
41. McKinsey, T. A.; Zhang, C. L.; Olson, E. N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase. Proc. Natl. Acad. Sci. USA 2000, 97, 14400-14405.
42. Lemercier, C.; Verdel, A.; Galloo, B.; Curtet, S.; Brocard, M. P.; Khochbin, S. mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. J. Biol. Chem. 2000, 275, 15594-15599.
43. Mal, A.; Sturniolo, M.; Schlitz, R. L.; Ghosh, M. K.; Harter, M. L. A Role for histone deacetylase HDAC1 in modulating the transcriptional activity of myod: Inhibition of the myogenic program. EMBO J. 2001, 20, 1739-1753.
44. Dressel, U.; Bailey, P. J.; Wang, S. C.; Downes, M.; Evans, R. M.; Muscat, G. E. A Dynamic role for HDAC-7 in MEF2 mediated muscle differentiation. J. Biol. Chem. 2001, 276, 17361-17366.
45. Saunders, N.; Dicker, A.; Popa, C.; Jones, S.; Dahler, A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999, 59, 399-404.
46. Qiu, L.,; Kelso, M. J.; Hansen, C.; West, M. L.; Fairlie, D. P.; Parsons, P, G. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 1999, 80, 1252-1258.
47. Miska, E. A.; Karlsson, C.; Langley, E.; Nielsen, S. J.; Pines, J; Kouzarides, T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 1999, 18, 5099-5107.
48. Wang, H. A.; Bertos, N. R.; Vezmar, M.; Pelletier, N.; Crosato, M.; Heng, H. H.; Th'ng, J.; Han, J.; Yang, X. J. HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol. 1999, 19, 7816-7827.
49. Zhou, X.; Richon, V. M.; Wang, A. H.; Yang, X. J.; Rifkind, R. A.; Marks, P. A. Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2 and its cellular localization is regulated by oncogenic Ras. Proc. Natl. Acad. Sci. USA 2000, 97, 14329-14333.
50. Grozinger, C. M.; Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. USA 2000, 97, 7835-7840.
51. Wang, A. H.; Kruhlak, M. J.; Wu, J.; Bertos, N. R.; Vezmar, M.; Posner, B. I.; Bazett-Jones, D. P.; Yang, X. Regulation of histone deacetylase 4 by binding of 14-3-3 proteins. Mol. Cell. Biol. 2000, 20, 6904-6912.
52. Wang, A. H.; Yang, X. J. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol. Cell. Biol. 2001, 21, 5992-6005.
53. McKinsey, T. A.; Zhang, C. L.; Olson, E. N. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases. Mol. Cell. Biol. 2001, 21, 6312-6321.
54. Morgan, D. O. Principles of CDK regulation. Nature 1995, 374, 131-134.
55. Gray-Bablin, J.; Zalvide, J.; Fox, M. P.; Knickerbocker, C. J.; DeCaprio, J. A.; Keyomarsi, K. Cyclin E, a redundant cyclin in breast cancer. Proc. Natl. Acad. Sci. USA 1996, 93, 15215-15220.
56. Sherr, C. J. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 2000, 60, 689-695.
57. Ohtsubo, M.; Theodoras, A. M.; Schumacher, J.; Roberts, J. M.; Pagano, M. Human cyclin E, a nuclear protein essential for the Gl-to-S phase transition. Mol. Cell. Biol. 1995, 15, 2612-2624.
58. Pagano, M.; Pepperkok, R.; Verde, F.; Ansorge, W.; Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992, 11, 961-971.
59. Strausfeld, U. P.; Howell, M.; Descombes, P.; Chevalier, S.; Rempel, R. E.; Adamczewski, J.; Maller, J. L.; Hunt, T.; Blow, J. J. Both cyclin A and cyclin E have S-phase promoting (SPF) activity in xenopus egg extracts. J. Cell Sci. 1996, 109, 1555-1563.
60. Goldstone, S.; Pavey, S.; Forrest, A.; Sinnamon, J.; Gabrielli, B. Cdc25-dependent activation of cyclin A/Cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. oncogene (in press).
61. Hu, B.; Mitra, J.; van den Heuvel, S.; Enders, G. H. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol. Cell. Biol. 2001, 21, 2755-2766.
62. Elledge, S. J. Cell cycle checkpoints: Preventing an identity crisis. Science 1996, 274, 1664-1672.
63. Ogryzko, V. V.; Wong, P.; Howard, B. H. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol. Cell. Biol. 1997, 17, 4877-4882.
64. O'Connell, M. J.; Walworth, N. C.; Carr, A. M. The G2-phase DNA-damage checkpoint. Trends Cell Biol. 2000, 10, 296-303.
65. Cenciarelli, C.; De Santa, F.; Puri, P. L.; Mattei, E.; Ricci, L.; Bucci, F.; Felsani, A.; Caruso, M. Critical role played by cyclin D3 in the myod-mediated arrest of cell cycle during myoblast differentiation. Mol. Cell. Biol. 1999, 19, 5203-5217.
66. Puri, P. L.; Sartorelli, V.; Yang, X. J.; Hamamori, Y. Y.; Ogryzko, V. V.; Howard, B. H.; Kedes, L.; Wang, J. Y.; Graessmann, A.; Nakatani, Y.; Levrero, M. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol. Cell. 1997, 1, 35-45.
67. Dunphy, E. L.; Johnson, T.; Auerbach, S. S.; Wang, E. H. Requirement for TAF(II)250 acetyltransferase activity in cell cycle progression. Mol. Cell. Biol. 2000, 20, 1134-1139.
68. Harbour, J. W.; Dean, D. C. Chromatin remodeling and Rb activity. Curr. Opin. Cell Biol. 2000, 12, 685-689.
69. Harbour, J. W.; Luo, R. X.; Dei Santi, A.; Postigo, A. A.; Dean, D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through Gl. Cell 1999, 98. 859-869.
70. Taddei, A.; Roche, D.; Sibarita, J. B.; Turner, B. M.; Almouzni, G. Duplication and maintenance of heterochromatin domains. J. Cell Biol. 1999, 147, 11153-1166.
71. Mello, J.A.; Almouzni, G. The ins and outs of nucleosome assembly. Curr. Opin. Genet. Dev. 2001, 11, 136-141.
72. Clarke, A. S.; Lowell, J. E.; Jacobson, S. J.; Pillus, L. Esa1p is an essential histone acetyltransferase required for cell cycle progression. Mol. Cell. Biol. 1999, 19, 2515-2526.
73. Megee, P. C.; Morgan, B. A.; Smith, M. M. Histone H4 and the maintenance of genome integrity. Genes Dev. 1995, 9, 1716-1727.
74. Howe, L.; Auston, D.; Grant, P.; John, S.; Cook, R. G.; Workman, J. L.; Pillus, L. Histone H3 Specific Acetyltransferases are Essential for Cell Cycle Progression. Genes Dev. 2001, 15, 3144-3154.
75. Vialard, J. E.; Gilbert, C. S.; Green, C. M.; Lowndes, N. F. The budding yeast Rad9 checkpoint protein is subjected to Mec1/Tel1-dependent hyperphosphorylation and interacts with Rad53 after DNA damage. EMBO J. 1998, 17, 5679-5688.
76. Bartl, S.; Taplick, J.; Lagger, G.; Khier, H.; Kuchler, K.; Seiser, C. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol. Cell. Biol. 1997, 17, 5033-5043.
77. Burgess, A. J.; Pavey, S.; Warrener, R.; Hunter, L. J.; Piva, T. J.; Musgrove, E. A.; Saunders, N.; Parsons, P. G.; Gabrielli, B. G. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 2001, 60, 828-837.
78. Richon, V. M.; Sandhoff, T. W.; Rifkind, R. A.; Marks, P. A. Histone deacetylase inhibitor selectively induces p21waf1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 2000, 97, 10014-10019.
79. Doetzlhofer, A.; Rotheneder, H.; Lagger, G.; Koranda, M.; Kurtev, V.; Brosch, G.; Wintersberger, E.; Seiser, C. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol. Cell. Biol. 1999, 19, 5504-5511.
80. Huang, L.; Sowa, Y.; Sakai, T.; Pardee, A. B. Activation of the p21WAF1/CIPI promoter independent of p53 by The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000, 19, 5712-5719.
81. Sambucetti, L. C.; Fischer, D. D.; Zabludoff, S.; Kwon, P. O.; Chamberlin, H.; Trogani, N.; Xu, H.; Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 1999, 274, 34940-34947.
82. Archer, S. Y.; Meng, S.; Shei, A.; Hodin, R. A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 6791-6796.
83. Rosato, R. R.; Wang, Z.; Gopalkrishnan, R. V.; Fisher, P. B.; Grant, S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukaemia cells (U937). Int. J. Oncol. 2001, 19, 181-191.
84. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett, D.; Sausville, E.; Blagosklonny, M. V.; Bates, S. E. p21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 2000, 83, 817-825.
85. Wharton W.; Savell, J.; Cress, W. D.; Seto, E.; Pledger, W. J. Inhibition of mitogenesis in Balb/C-3T3 cells by trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J. Biol. Chem. 2000, 275, 33981-33987.
86. Kim, Y. B.; Lee, K. H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999, 18, 2461-2470.
87. Lallemand, F.; Courilleau, D.; Buquet-Fagot, C.; Atfi, A.; Montagne, M. N; Mester, J. Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Exp. Cell Res. 1999, 247, 432-440.
88. Qiu, L.; Burgess, A.; Fairlie, D. P.; Leonard, H.; Parsons, P. G.; Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 2000, 11, 2069-2083.
89. Sowa, Y.; Orita, T.; Minamikawa, S.; Nakano, K.; Mizuno, T.; Nomura, H.; Sakai, T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 1997, 241, 142-150.
90. Taddei, A.; Maison, C.; Roche, D.; Almouzni, G. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol. 2001, 3, 114-120.
91. Howman, E. V.; Fowler, K. J.; Newson, A. J.; Redward, S.; MacDonald, A. C.; Kalitsis, P.; Choo, K. H. Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice. Proc. Natl. Acad. Sci. USA 2000, 97, 1148-1153.
92. Schaar, B. T.; Chan, G. K.; Maddox, P.; Salmon, E. D.; Yen, T. J. CENP-E function at kinetochores is essential for chromosome alignment. J. Cell Biol. 1997, 139, 1373-1382.
93. Ekwall, K.; Olsson, T.; Turner, B. M.; Cranston, G.; Allshire, R. C. Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres. Cell 1997, 91, 1021-1032.
94. Vrana, J. A.; Decker, R. H.; Johnson, C. R.; Wang, Z.; Jarvis, W. D.; Richon, V. M.; Ehinger, M.; Fisher, P. B.; Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999, 18, 7016-7025.
95. Bernhard, D.; Ausserlechner, M. J.; Tonko, M.; Loffler, M.; Hartmann, B. L.; Csordas, A.; Kofler, R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J. 1999, 13, 1991-2001.
96. Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D.; Sutton, V. R.; Tainton, K. M.; Kofler, R.; Smyth, M. J.; Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 2001, 98, 10833-10838.
97. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis. A link between cancer genetics and chemotherapy. Cell 2002, 108, 153-164.
98. Green, D. R. Apoptotic pathways: Paper wraps stone blunis scissors, Cell 2000, 102, 1-4.
99. Strasser, A.; Harris, A. W.; Huang, D. C.; Krammer, P. H.; Cory, S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995, 14, 6136-6147.
100. Ruefli, A. A.; Smyth, M. J.; Johnstone, R. W. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000, 95, 2378-2385.
101. Trapani, J. A.; Davis, J.; Sutton, V. R.; Smyth, M. J. Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr. Opin. Immunol. 2000, 12, 323-329.
102. Glick, R. D.; Swendeman, S. L.; Coffey, D. C.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.; La Quaglia, M. P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 1999, 59, 4392-4399.
103. Kwon, S. H.; Ahn, S. H.; Kim, Y. K.; Bae, G. U. Yoon, J. W.; Hong, S.; Lee, H. Y.; Lee, Y. W.; Lee, H. W.; Han, J. W. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 2002, 277, 2073-2080.
104. Bernhard, D.; Skvortsov, S.; Tinhofer, I.; Hubl, H.; Greil, R.; Csordas, A.; Kofler, R. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 2001, 8, 1014-1021.
105. Marsters, S. A.; Pitti, R. M.; Donahue, C. J.; Ruppert, S.; Bauer, K. D.; Ashkenazi, A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 1996, 6, 750-752.
106. Wang, R.; Brunner, T.; Zhang, L.; Shi, Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 1998, 17, 1503-1508.
107. Cao, X. X.; Mohuiddin, I.; Ece, F.; McConkey, D. J.; Smythe, W. R. Histone deacetylase inhibitor downregulation of bcl-x1 gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell. Mol. Biol. 2001, 25, 562-568.
108. Kramer, O. H.; Gottlicher, M.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001, 12, 294-300.
109. Suzuki, T.; Yokozaki, H.; Kuniyasu, H.; Hayashi, K.; Naka, K.; Ono, S.; Ishikawa, T.; Tahara, E.; Yasui, W. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer 2000, 88, 992-997.
110. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA 2001, 98, 87-92.
111. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 2001, 8, 1505-1511.
112. Komatsu, Y.; Tomizaki, K. Y.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic acid containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001, 61, 4459-4466.
113. He, L. Z.; Tolentino, T.; Grayson, P.; Zzhong, S.; Warrell, R. P.; Rifkind, R. A., Marks, P. A.; Richon, V. M.; Pandolfi, P. P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 2001, 9, 1321-1330.
114. Coffey, D. C.; Kutko, M. C.; Glick, R. D.; Butler, L. M.; Heller, G.; Rifkind, R. A.; Marks, P. A.; Richon, V. M.;, La Quaglia, M. P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts. In vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 2001, 61, 3591-3594.
115. Kitazano, M.; Goldsmith, M. E.; Aikou, T.; Bates, S.; Fojo, T. Enhanced adenovirus transgene expression in malignant cells treated with histone deacetylase inhibitor FR901228. Cancer Res. 2001, 61, 6328-6330.
116. Warrell, R. P.; He, L. Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targetting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1998, 90, 1621-1625.
117. Piekarz, R. L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W. H.; Dahmoush, L.; Kingma, D. M.; Turner, M. L.; Altemus, R.; Bates, S. E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell Lymphoma: A Case Report. Blood 2001, 98, 2865-2868.
118. Douillard, J. Y.; Bennouna, J.; Vavasseur, F.; Deporte-Fety, R.; Thomare, P. F.; Meflah, K. Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. Cancer Immunol. Immunother. 2000, 49, 56-61.
119. Gore, S. D.; Carducci, M. A. Modifying histones to tame cancer: A clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp. Opin. Invest. Drugs 2000, 9, 2923-2934.